FILTER
FILTERED INTERVIEW RESULTS
Paulo Reis
MANAGING PARTNER, EY MOZAMBIQUE
EY Mozambique sees opportunity to capitalize on the extractive industries to benefit the country’s development of other sectors.
Adry Nzonzimbu
DIRECTOR, MINEQUIP
Minequip prepares to transform its operations in the DRC with the opening of a new warehouse and repair facility this year.
Deon Heyns
CEO, CONGO EQUIPMENT
Congo Equipment is the official CAT dealer for the mining region of DRC.
Normand Champigny
PRESIDENT & CEO, SPHINX RESOURCES
Sphinx discusses its shift in focus to a zinc project in southwestern Québec.
Peter Ivison
CHIEF STRATEGY OFFICER, INX SOFTWARE
INX Software uses state-of-the-art technology to build workforce management systems that improves the working lives of employees & contractors.
Louison Kiyombo
PARTNER, KPMG
KPMG draws on global experience and local expertise to help clients navigate the DRC’s complicated legislative framework.
Cécile Amory
GENERAL MANAGER, MINING CONTRACTING SERVICES CONGO (MCSC)
Local contracting firm MCSC discusses its strategy for ensuring sustainable growth in the risky DRC mining game.
Elizabeth Gaines
GROUP CEO, FORTESCUE METALS GROUP
Australia-based Fortescue Metals Group is the fourth largest iron ore producer in the world.
Susa Maleba & Wouter Jordaan
DRC COUNTRY MANAGER & PARTNER AND PRINCIPAL ENVIRONMENTAL SCIENTIST, SRK CONSULTING (SA) AND DIRECTOR OF SRK CONSULTING (DRC)
International consulting company SRK discusses expectations for the future of the DRC’s mining industry.
Ivan Bebek
EXECUTIVE CHAIRMAN, AURYN RESOURCES
Auryn Resources is a technically driven, capital efficient exploration company focused on delivering shareholder value through accretive project acquisition.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
